New pill shows 60 per cent LDL reduction in trials: Cardiologists break down if it reduces heart attack risk

High levels of low-density lipoprotein cholesterol (LDL-C) are a key risk factor for cardiovascular disease, which continues to be one of the leading causes of illness and death globally. LDL-C can accumulate in the walls of arteries over time, causing a condition known as atherosclerosis, in which the arteries become narrowed and blood flow is restricted. This condition increases the likelihood of heart attacks, strokes, and other cardiovascular events. Management of elevated cholesterol generally involves lifestyle interventions, including dietary modification, increased physical activity, and cessation of smoking. However, for many patients, these measures alone are not sufficient to achieve target LDL-C levels. Statins have traditionally been the primary pharmacological treatment, but additional therapy is often needed. Oral PCSK9 inhibitors, including enlicitide, are a newer option for lowering LDL-C without injections.

How the pill works

Enlicitide is an orally administered PCSK9 inhibitor. PCSK9 is a protein that binds to LDL receptors in the liver, promoting their breakdown. LDL receptors are responsible for removing LDL-C from the bloodstream. When PCSK9 reduces the number of LDL receptors, less cholesterol is cleared from circulation, resulting in higher blood levels of LDL-C. By blocking PCSK9, enlicitide allows more LDL receptors to remain active, which increases the liver’s capacity to remove LDL-C from the blood. The oral formulation provides a daily pill option, compared with injectable PCSK9 inhibitors that are typically administered every two to four weeks. This method avoids procedural requirements associated with injections, such as healthcare visits or self-administration techniques, and may simplify long-term cholesterol management. This daily dosing approach may also help patients maintain consistent LDL reduction, especially those already using statins or ezetimibe. It offers a more routine-friendly way to manage hypercholesterolemia, familial cholesterol disorders, and overall cardiovascular risk.

How effective the oral PCSK9 inhibitor is

A phase 3 clinical trial published in JAMA evaluated the efficacy of enlicitide in adults with heterozygous familial hypercholesterolemia, a genetic condition associated with high LDL-C and increased cardiovascular risk. The trial enrolled 303 participants across 17 countries, all of whom were already receiving statin therapy. Participants were randomly assigned to receive either enlicitide or a placebo for 24 weeks, in addition to their ongoing treatment. The primary endpoint of the trial was the percentage change in LDL-C levels from baseline to week 24. Participants who received enlicitide experienced an average LDL-C reduction of 58.2 per cent, while those receiving placebo showed a 2.6 per cent increase. This demonstrates a substantial reduction in LDL-C with oral PCSK9 inhibition, comparable to reductions observed with injectable PCSK9 inhibitors.

Safety and side effects associated with the oral PCSK9 inhibitor

In the clinical trial, most reported side effects of enlicitide were mild to moderate. Some participants experienced gastrointestinal symptoms such as nausea or temporary stomach discomfort, which generally resolved without intervention. A small number experienced minor adverse events related to trial procedures, including laboratory testing or sample collection. No serious liver, cardiac, or neurological complications were reported during the 24-week period. Oral administration eliminates injection-related issues such as site reactions, pain, or procedural complications. Overall, enlicitide was considered well tolerated, supporting its use in a controlled clinical setting.

What is the potential impact on heart attack and stroke risk

Although the trial demonstrated significant LDL-C reduction, the direct impact of enlicitide on heart attack, stroke, or other major cardiovascular events is still being studied. Lowering LDL-C is generally associated with reduced cardiovascular risk, but long-term outcome studies are required to confirm whether oral PCSK9 inhibitors directly reduce the incidence of these events. Ongoing research will help determine the extent to which LDL-C reduction translates into prevention of heart attacks and strokes in broader patient populations.

What are the benefits of daily oral dosing are

Oral administration may offer practical advantages in cholesterol management. Daily pills eliminate the need for injections, potentially simplifying medication schedules and supporting adherence for patients managing multiple therapies. Oral therapy may also expand access to treatment in regions where injectable PCSK9 inhibitors are difficult to administer due to infrastructure limitations. Patients who are reluctant to use injections may be more likely to initiate or continue therapy when an oral option is available. Additionally, oral administration reduces the need for procedural monitoring and associated healthcare resources.

Future research on oral PCSK9 inhibitors

Researchers are conducting long-term studies to evaluate the effects of oral PCSK9 inhibitors on cardiovascular outcomes, including heart attacks, strokes, and other complications. Additional studies are assessing the interaction of enlicitide with other cholesterol-lowering medications to identify optimal combination therapies. Genetic and individual factors that influence response to oral PCSK9 inhibitors are also being investigated, with the goal of tailoring therapy to specific patient profiles. Long-term safety monitoring is ongoing to identify rare adverse events and provide guidance for extended use of oral therapy.

Implications for public health

Oral PCSK9 inhibitors may have implications beyond individual patients. By simplifying administration and potentially improving adherence, oral therapy could increase the proportion of patients achieving LDL-C targets, which may contribute to reductions in cardiovascular disease incidence at a population level. Access to oral therapy in regions with limited injection-based care could also address healthcare disparities, allowing a broader patient population to receive advanced cholesterol management.

Ongoing studies will provide further evidence on long-term outcomes, combination therapy approaches, and patient-specific responses. Oral PCSK9 inhibitors offer a practical treatment option and may improve adherence and access to cholesterol-lowering therapy.




Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult a healthcare professional before making any changes to your diet, medication, or lifestyle.



Also Read | 6 popular “healthy” foods that are harmful for your heart

Get an chance to win ₹5000 Amazon Voucher by taking part in India's Biggest Habit Index! Take the survey here